Welcome to the official InxMed website
Pipeline

Pipeline

>
Pipeline

Pipeline

Asset Modality / Target Regimen Indication Discovery Pre-Clinical FIH POC Pivotal Status
IN10018 Small molecular FAK inhibitor + PLD

Platinum Resistant Ovarian Cancer

 
Pivotal study initiated in 2022
+ MEKi

RAS-mu Tumor

 
PoC to be completed in 2022
Regimen undisclosed

PROC, TNBC, HNSCC and Other PLD Indicated Cancers

 
PoC expected in 2023
+ KRASG12C inhibitor

KRAS G12C-mu Solid Tumor

 
PoC expected in 2023

+ IO bispecific

PDAC

 
CTP approved Q3 2022
3rd EGFR TKI

EGFR-mu NSCLC

 
PoC to be initiated in 2022
IN30705 ADC Targeting FAP Mono / Combo Solid Tumor
 
CTP expected Q4 2022
INES103 Antibody Target undisclosed Combo Solid Tumor
 
CTP expected Q4 2022
IN30718 ADC Target undisclosed Mono Solid Tumor
 
PCC nominated in 2023
IN20019 Small molecular Target undisclosed Mono Solid Tumor
 
PCC nominated in 2023

IN10018

IN10018 is a highly potent and selective inhibitor of the focal adhesion kinase (FAK). Anti-tumor activities of IN10018 have been demonstrated in multiple animal models for human cancers. More than 250 patients have been dosed and IN10018 has showed its safety and promising efficacy signal in platinum ovarian cancer and NRAS melanoma.

IN30705

IN30705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment. 

INES103

INES103 is an injectable recombinant humanized VHH (single variable domain of heavy chain, VHH)-Fc fusion protein against tumor associate macrophage(TAM)related target, to be administered for treatment of advanced or metastatic solid tumor and hematological malignancies. INES103 is designed to improve tissue penetration against solid tumors.

 InxMed

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

MESSAGE

Follow Us:

CopyRight © 2022 InxMed All Rights Reserved.

Powered by: 300.cn | SEO